Western blot analysis of PI3K pathway components revealed that alpelisib plus anti-HER2 treatments were accompanied by a more pronounced decrease in p-S6K protein levels compared with alpelisib or anti-HER2 therapy alone in all HER2+ BC cell lines. This evidence concerns the gene PIK3CD and breast cancer.